Cargando…

One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19

PURPOSE: To assess health-related quality of life (HRQoL) and its associated factors in patients who survived COVID-19 and to assess a prospective evaluation of the prevalence and severity of their depression and anxiety symptoms. METHODS: We followed up a sample of hospitalized patients who survive...

Descripción completa

Detalles Bibliográficos
Autores principales: Huarcaya-Victoria, Jeff, Alarcon-Ruiz, Christoper A., Barzola-Farfán, William, Cruzalegui-Bazán, Claudia, Cabrejos-Espinoza, Michaell, Aspilcueta-Montoya, Gabriela, Cornero-Quispe, Feleydi, Salazar-Bellido, Javier, Villarreal, Beltrán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358105/
https://www.ncbi.nlm.nih.gov/pubmed/35939252
http://dx.doi.org/10.1007/s11136-022-03208-w
_version_ 1784763860967751680
author Huarcaya-Victoria, Jeff
Alarcon-Ruiz, Christoper A.
Barzola-Farfán, William
Cruzalegui-Bazán, Claudia
Cabrejos-Espinoza, Michaell
Aspilcueta-Montoya, Gabriela
Cornero-Quispe, Feleydi
Salazar-Bellido, Javier
Villarreal, Beltrán
author_facet Huarcaya-Victoria, Jeff
Alarcon-Ruiz, Christoper A.
Barzola-Farfán, William
Cruzalegui-Bazán, Claudia
Cabrejos-Espinoza, Michaell
Aspilcueta-Montoya, Gabriela
Cornero-Quispe, Feleydi
Salazar-Bellido, Javier
Villarreal, Beltrán
author_sort Huarcaya-Victoria, Jeff
collection PubMed
description PURPOSE: To assess health-related quality of life (HRQoL) and its associated factors in patients who survived COVID-19 and to assess a prospective evaluation of the prevalence and severity of their depression and anxiety symptoms. METHODS: We followed up a sample of hospitalized patients who survived COVID-19 at 3 and 12 months after discharge. We assessed HRQoL (Euroqol-5D-5L) through telephone interviews. Any problem in any dimension of Euroqol-5D-5L was considered as low HRQoL. The depression and anxiety symptoms were measured using the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 tools, respectively. We estimated the adjusted prevalence ratios (aPR) to low HRQoL using Poisson regression and the changes on their depression and anxiety symptoms during the follow-up. RESULTS: We included 119 patients with a mean follow-up time of 363.6 days. 74% of the participants had low HRQoL at one year after hospital discharge and were associated with being ≥ 41 years old (aPR: 1.95), having a previous history of psychiatric diagnoses before COVID-19 infection (aPR: 1.47), having any COVID-19 symptom during the follow-up at one year (aPR: 1.84), and having a family member who had died from COVID-19 during the first wave (aPR: 1.24). In addition, the clinically relevant depression symptoms were frequent, and they increased from 3 (14.3%) to 12 months (18.5%). CONCLUSION: One year after COVID-19 hospitalization discharge, patients had low HRQoL, and their depression symptoms increased. These findings acknowledge the need to provide services that adequately address mental health sequels and HRQoL to reduce the burden of the COVID-19.
format Online
Article
Text
id pubmed-9358105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93581052022-08-09 One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19 Huarcaya-Victoria, Jeff Alarcon-Ruiz, Christoper A. Barzola-Farfán, William Cruzalegui-Bazán, Claudia Cabrejos-Espinoza, Michaell Aspilcueta-Montoya, Gabriela Cornero-Quispe, Feleydi Salazar-Bellido, Javier Villarreal, Beltrán Qual Life Res Article PURPOSE: To assess health-related quality of life (HRQoL) and its associated factors in patients who survived COVID-19 and to assess a prospective evaluation of the prevalence and severity of their depression and anxiety symptoms. METHODS: We followed up a sample of hospitalized patients who survived COVID-19 at 3 and 12 months after discharge. We assessed HRQoL (Euroqol-5D-5L) through telephone interviews. Any problem in any dimension of Euroqol-5D-5L was considered as low HRQoL. The depression and anxiety symptoms were measured using the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 tools, respectively. We estimated the adjusted prevalence ratios (aPR) to low HRQoL using Poisson regression and the changes on their depression and anxiety symptoms during the follow-up. RESULTS: We included 119 patients with a mean follow-up time of 363.6 days. 74% of the participants had low HRQoL at one year after hospital discharge and were associated with being ≥ 41 years old (aPR: 1.95), having a previous history of psychiatric diagnoses before COVID-19 infection (aPR: 1.47), having any COVID-19 symptom during the follow-up at one year (aPR: 1.84), and having a family member who had died from COVID-19 during the first wave (aPR: 1.24). In addition, the clinically relevant depression symptoms were frequent, and they increased from 3 (14.3%) to 12 months (18.5%). CONCLUSION: One year after COVID-19 hospitalization discharge, patients had low HRQoL, and their depression symptoms increased. These findings acknowledge the need to provide services that adequately address mental health sequels and HRQoL to reduce the burden of the COVID-19. Springer International Publishing 2022-08-08 2023 /pmc/articles/PMC9358105/ /pubmed/35939252 http://dx.doi.org/10.1007/s11136-022-03208-w Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Huarcaya-Victoria, Jeff
Alarcon-Ruiz, Christoper A.
Barzola-Farfán, William
Cruzalegui-Bazán, Claudia
Cabrejos-Espinoza, Michaell
Aspilcueta-Montoya, Gabriela
Cornero-Quispe, Feleydi
Salazar-Bellido, Javier
Villarreal, Beltrán
One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title_full One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title_fullStr One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title_full_unstemmed One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title_short One-year follow-up of depression, anxiety, and quality of life of Peruvian patients who survived COVID-19
title_sort one-year follow-up of depression, anxiety, and quality of life of peruvian patients who survived covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358105/
https://www.ncbi.nlm.nih.gov/pubmed/35939252
http://dx.doi.org/10.1007/s11136-022-03208-w
work_keys_str_mv AT huarcayavictoriajeff oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT alarconruizchristopera oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT barzolafarfanwilliam oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT cruzaleguibazanclaudia oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT cabrejosespinozamichaell oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT aspilcuetamontoyagabriela oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT corneroquispefeleydi oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT salazarbellidojavier oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19
AT villarrealbeltran oneyearfollowupofdepressionanxietyandqualityoflifeofperuvianpatientswhosurvivedcovid19